Anti-folr1 nanobodies and derivatives and uses thereof

By developing anti-FOLR1 nanobodies and their derivatives, the problems of insufficient affinity and unsatisfactory kinetics of existing antibodies in tumor therapy have been solved. This has enabled highly efficient targeted binding and killing of FOLR1-positive tumor cells, reduced the risk of immunogenicity, and improved the efficacy of tumor therapy and the potential for drug development.

CN122404560APending Publication Date: 2026-07-17BIOINTRON BIOLOGICAL INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202610758962.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-29
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing anti-FOLR1 antibodies suffer from insufficient affinity, unsatisfactory binding kinetics, rapid dissociation rate, and high immunogenicity risk in tumor treatment, which limits their application efficacy and drug development potential in targeted tumor therapy.

Method used

An anti-FOLR1 nanobody and its derivatives were developed, containing a specific CDR sequence and a humanized variant. The high affinity and stable kinetic characteristics were verified by ELISA, flow cytometry and surface plasmon resonance technology. A bispecific T cell connector (TCE) was constructed to enhance the targeted therapeutic effect on FOLR1 positive tumor cells.

Benefits of technology

It achieves highly efficient targeted binding and killing of FOLR1-positive tumor cells, reduces the risk of immunogenicity, and improves the sustainability and safety of tumor targeted therapy. It is applicable to the development of biological drugs such as ADCs and bispecific antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404560A_ABST
    Figure CN122404560A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and relates to an anti-FOLR1 nanobody and derivatives and uses thereof. The nanobody and derivatives can specifically bind to FOLR1 protein with high affinity and effectively recognize FOLR1 positive tumor cells. In a T cell-mediated killing experiment, a bispecific T cell engager constructed by the anti-FOLR1 nanobody and an anti-CD3 nanobody can effectively induce specific killing of FOLR1 positive tumor cells (such as T47D) at a low concentration. A humanized variant of the anti-FOLR1 nanobody obtained based on a CDR grafting strategy has an affinity at the nanomolar (nM) level, stable binding kinetic characteristics, low immunogenicity risk and high clinical application potential. The antibody has good drugability and can be used for targeted treatment and diagnosis of FOLR1 positive related tumors.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-CD3 nano antibody capable of activating T cell activity as well as preparation method and application of anti-CD3 nano antibody

    CN119661713A